Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Children With Refractory Solid Tumors or Leukemias
NCT01445080Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of sorafenib in solid tumor, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 2 more (3 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level up to 28 days, Number of Patients With Treatment-related Adverse Events up to 2 years and 6 more. Started May 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
solid tumoracute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)juvenile myelomonocytic leukemia (JMML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT01445080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445080.